From: Market Insider
22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company focused on tobacco harm reduction and Very Low Nicotine tobacco, announced today that the National Institute on Drug Abuse (NIDA), the U.S. Food and Drug Administration (FDA), and public health researchers have requested a new, significant quantity of 22nd Century’s proprietary SPECTRUM® research cigarettes. In coordination with NIDA, FDA, and others, RTI International has submitted an order to 22nd Century for 3.6 million SPECTRUM® research cigarettes.
RTI’s newest SPECTRUM® order comes on the heels of the close of the FDA’s public comment period for the FDA’s Advanced Notice of Proposed Rulemaking (ANPRM) to establish a rule that will require that all cigarettes sold in the United States contain only minimally or non-addictive levels of nicotine. While the FDA is pressing ahead with its rule-making process, 22nd Century is simultaneously advancing its historic Modified Risk Tobacco Product (MRTP) application for the Company’s proprietary “BRAND A” Very Low Nicotine Content (VLNC) cigarettes. 22nd Century will file its MRTP application before the end of this year.
Read Complete Article [Emphasis added]